Every AXLRx Fabry Disease report, across 9 report types and 3 markets. Each is scoped to your asset and verified to a live source.
Classic childhood-onset Fabry versus a largely undiagnosed later-onset cardiac form, an X-linked organ timeline, and the ~35–50% amenable-mutation treatment gate.
A genetic test gates oral migalastat, IV enzyme replacement sits in Part B, and Fabrazyme has no US biosimilar — though the IRA's orphan-drug exclusion shields it from Medicare price negotiation.
Two IV enzyme replacement therapies meet an oral chaperone that only ~35–50% of patients can take — and pegunigalsidase now challenges Fabrazyme's two-decade lead.
Oral migalastat versus IV enzyme replacement, and how pegunigalsidase's newly NICE-recommended suboptimal-responder appraisal (TA915) reshapes NHS-commissioned Fabry therapy.
5,000-10,000 diagnosed US classic Fabry patients, a 35-50% amenable-mutation gate to oral therapy, and a treated population still 60-65% on enzyme replacement. This funnel starts at diagnosis because no defensible undiagnosed estimate exists yet.
700-900 NHS-diagnosed Fabry patients split cleanly: roughly 600 on enzyme replacement, about 200 (25%) on oral migalastat, and free NHS cascade testing that adds 3-4 diagnosed relatives per index case.
GCC male Fabry prevalence runs 1:20,000-30,000, elevated by founder mutations, yet only 200-300 patients are diagnosed against a true burden estimated 3-5 times higher, and female diagnosis lags under half the male rate.
Agalsidase beta was never formally appraised by NICE, while migalastat's HST4 recommendation (2016) was the first oral mutation-specific rare disease therapy NICE approved; together they underpin an estimated £144M NHS Fabry programme, with a £70-130K/patient/year switch incentive still unrealised at scale.
Five named NHS lysosomal storage disorder centres, and Royal Free London's National Fabry Service, named NICE's appointed clinical expert for both migalastat's HST4 and pegunigalsidase alfa's TA915. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.
KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC, and its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it.
The ADA-positive suboptimal-agalsidase-responder niche (200–400 US patients) is Fabry's only clean pre-launch opening.
Why NPHC has a 72%-cost-reduction financial incentive to switch amenable-mutation Fabry patients from ERT to migalastat — and why a single HEK293 assay lab in the entire GCC is the only thing standing in the way.
Arabian Peninsula founder mutations, the female diagnosis gap, and the HEK assay bottleneck limiting oral chaperone therapy access across the GCC.
Fabrazyme's orphan-drug exclusion under the IRA shields it from Medicare price negotiation entirely, and no rebate or net-price figure is disclosed anywhere in the primary record for any Fabry therapy. The orphan exclusion, not a discount ladder, is what a Fabry pricing strategy has to be built around.
UK Fabry disease is commissioned through three different NICE and NHS routes at once: no formal NICE technology appraisal for either enzyme replacement therapy, a Highly Specialised Technologies recommendation (HST4, 2016) for migalastat, and a standard technology appraisal (TA915, 2023) for pegunigalsidase alfa. A new entrant inherits no single reusable comparator or price benchmark.
The NHS lysosomal-storage-disorder specialist network, UK Fabry Outcome Survey longitudinal data, and both NHS-commissioned ERT and NICE HST4-recommended oral chaperone therapy across an estimated 800-patient UK cohort.
Why the £144M NHS Fabry market, the largest in Europe, already has two established agents, and why an ADA-positive or female-heterozygote niche, not general ERT improvement, is the only viable UK entry point.
Agalsidase beta runs an estimated £150-250K per patient per year against migalastat's £80-120K, a £70-130K annual switch saving NICE has already quantified but the NHS has not captured at scale, with pegunigalsidase's TA915 commercial arrangement now setting a third price point.
NPHC pays roughly SAR 1.2-2.4M per patient per year for enzyme replacement against SAR 400-600K for migalastat, a 72% differential that gives NPHC a direct financial incentive to switch eligible patients, capped almost entirely by a single-laboratory diagnostic bottleneck rather than by price.
Roughly 5,000-10,000 diagnosed US Fabry patients split first by GLA amenability (35-50% oral-eligible) and then by ADA status, narrowing to a precise 200-400 patient addressable niche that a Fabrazyme-anchored $250-350K WAC makes commercially calculable.
700-900 diagnosed UK Fabry patients split roughly 600 ERT to 200 oral, inside which two further niches sit: 50-80 ADA-positive suboptimal responders and 80-120 undertreated symptomatic female heterozygotes, against a £144M NHS spend anchor.
GCC is a two-ERT Fabry market (agalsidase alfa via the EMA pathway alongside agalsidase beta), while migalastat's oral advantage, covering 35-50% of patients, is bottlenecked by the single GCC lab that can run the amenable-mutation assay.
200-300 diagnosed GCC Fabry patients against a true prevalence estimated 3-5 times higher, undercounted because a single regional laboratory gates the amenable-mutation test and female heterozygotes are diagnosed at under half the male rate.
Both approved Fabry ERTs are already NPHC-covered in GCC — the constraint is finding an unaddressed niche: the 30-50 patient ADA-positive cohort or the HEK-assay bottleneck that locks non-KFSH&RC patients out of oral therapy.
AXLRx publishes Disease Landscape, Payer & HTA, Competitive Intelligence, Patient Flow Model, KOL Mapping, Launch Readiness, Pricing Strategy Model, HTA Strategy Model, and Market Sizing Model for Fabry Disease. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Fabry Disease coverage spans United States, United Kingdom, and GCC (Gulf). Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Fabry Disease reports were updated July 2026.